Cargando…

Assessment of glycemic control in patients with type 2 diabetes mellitus treated with metformin–sulfonylurea combination: Results of a multicenter, cross-sectional, observational study in Korea

AIMS/INTRODUCTION: To assess the current status of glycemic control in patients with type 2 diabetes treated with a combination of metformin and sulfonylurea for >3 months, as measured by glycosylated hemoglobin (HbA1c). MATERIALS AND METHODS: Data on patient demographics, diabetic complications,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sin Gon, Hahm, Jong Ryeal, Kim, Duk Kyu, Cho, Sung Rae, Choi, Dong Seop
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420564/
https://www.ncbi.nlm.nih.gov/pubmed/25969717
http://dx.doi.org/10.1111/jdi.12284
_version_ 1782369745541005312
author Kim, Sin Gon
Hahm, Jong Ryeal
Kim, Duk Kyu
Cho, Sung Rae
Choi, Dong Seop
author_facet Kim, Sin Gon
Hahm, Jong Ryeal
Kim, Duk Kyu
Cho, Sung Rae
Choi, Dong Seop
author_sort Kim, Sin Gon
collection PubMed
description AIMS/INTRODUCTION: To assess the current status of glycemic control in patients with type 2 diabetes treated with a combination of metformin and sulfonylurea for >3 months, as measured by glycosylated hemoglobin (HbA1c). MATERIALS AND METHODS: Data on patient demographics, diabetic complications, HbA1c, fasting plasma glucose (FPG) and type of treatment were collected in this multicenter, cross-sectional, non-interventional study. RESULTS: From April 2008 to February 2009, 5,628 patients were recruited from 299 centers in Korea. Patients characteristics (mean ± SD) were as follows: age 58.4 ± 10.8 years, duration of diabetes 6.1 ± 4.7 years, body mass index 24.7 ± 2.9 kg/m(2), HbA1c 7.77 ± 1.22%, FBG 147.4 ± 46.5 mmol/L and FPG 164.0 ± 54.3 mmol/L. The most common diabetic complication was neuropathy (22.5%), followed by retinopathy (18.3%) and microalbuminuria (16.1%). Just 1,524 (27.1%) patients achieved HbA1c ≤7%. A higher number of patients (32.6%) treated by endocrinologists achieved HbA1c ≤7% than those treated by internists (24.4%) and primary care physicians (23.2%). In multivariate analyses, diabetic retinopathy (odds ratio 0.455, 95% confidence interval 0.341–0.606), nephropathy (odds ratio 0.639, 95% confidence interval 0.43–0.949), diabetes for ≥5 years (odds ratio 0.493, 95% confidence interval 0.4–0.606) and older age added by 1 year (odds ratio 1.019, 95% confidence interval 1.01–1.029) was significantly associated with achieving target HbA1c. In addition, treatment by endocrinologists rather than internists significantly increased chances of achieving target HbA1c (odds ratio 1.417, 95% confidence interval 1.146–1.751). CONCLUSIONS: The majority of patients with type 2 diabetes in Korea had inadequate glycemic control, despite receiving a combination of metformin and sulfonylurea.
format Online
Article
Text
id pubmed-4420564
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-44205642015-05-12 Assessment of glycemic control in patients with type 2 diabetes mellitus treated with metformin–sulfonylurea combination: Results of a multicenter, cross-sectional, observational study in Korea Kim, Sin Gon Hahm, Jong Ryeal Kim, Duk Kyu Cho, Sung Rae Choi, Dong Seop J Diabetes Investig Articles AIMS/INTRODUCTION: To assess the current status of glycemic control in patients with type 2 diabetes treated with a combination of metformin and sulfonylurea for >3 months, as measured by glycosylated hemoglobin (HbA1c). MATERIALS AND METHODS: Data on patient demographics, diabetic complications, HbA1c, fasting plasma glucose (FPG) and type of treatment were collected in this multicenter, cross-sectional, non-interventional study. RESULTS: From April 2008 to February 2009, 5,628 patients were recruited from 299 centers in Korea. Patients characteristics (mean ± SD) were as follows: age 58.4 ± 10.8 years, duration of diabetes 6.1 ± 4.7 years, body mass index 24.7 ± 2.9 kg/m(2), HbA1c 7.77 ± 1.22%, FBG 147.4 ± 46.5 mmol/L and FPG 164.0 ± 54.3 mmol/L. The most common diabetic complication was neuropathy (22.5%), followed by retinopathy (18.3%) and microalbuminuria (16.1%). Just 1,524 (27.1%) patients achieved HbA1c ≤7%. A higher number of patients (32.6%) treated by endocrinologists achieved HbA1c ≤7% than those treated by internists (24.4%) and primary care physicians (23.2%). In multivariate analyses, diabetic retinopathy (odds ratio 0.455, 95% confidence interval 0.341–0.606), nephropathy (odds ratio 0.639, 95% confidence interval 0.43–0.949), diabetes for ≥5 years (odds ratio 0.493, 95% confidence interval 0.4–0.606) and older age added by 1 year (odds ratio 1.019, 95% confidence interval 1.01–1.029) was significantly associated with achieving target HbA1c. In addition, treatment by endocrinologists rather than internists significantly increased chances of achieving target HbA1c (odds ratio 1.417, 95% confidence interval 1.146–1.751). CONCLUSIONS: The majority of patients with type 2 diabetes in Korea had inadequate glycemic control, despite receiving a combination of metformin and sulfonylurea. BlackWell Publishing Ltd 2015-05 2014-11-17 /pmc/articles/PMC4420564/ /pubmed/25969717 http://dx.doi.org/10.1111/jdi.12284 Text en © 2014 The Authors. Journal of Diabetes Investigation published by Asian Association of the Study of Diabetes (AASD) and Wiley Publishing Asia Pty Ltd http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Kim, Sin Gon
Hahm, Jong Ryeal
Kim, Duk Kyu
Cho, Sung Rae
Choi, Dong Seop
Assessment of glycemic control in patients with type 2 diabetes mellitus treated with metformin–sulfonylurea combination: Results of a multicenter, cross-sectional, observational study in Korea
title Assessment of glycemic control in patients with type 2 diabetes mellitus treated with metformin–sulfonylurea combination: Results of a multicenter, cross-sectional, observational study in Korea
title_full Assessment of glycemic control in patients with type 2 diabetes mellitus treated with metformin–sulfonylurea combination: Results of a multicenter, cross-sectional, observational study in Korea
title_fullStr Assessment of glycemic control in patients with type 2 diabetes mellitus treated with metformin–sulfonylurea combination: Results of a multicenter, cross-sectional, observational study in Korea
title_full_unstemmed Assessment of glycemic control in patients with type 2 diabetes mellitus treated with metformin–sulfonylurea combination: Results of a multicenter, cross-sectional, observational study in Korea
title_short Assessment of glycemic control in patients with type 2 diabetes mellitus treated with metformin–sulfonylurea combination: Results of a multicenter, cross-sectional, observational study in Korea
title_sort assessment of glycemic control in patients with type 2 diabetes mellitus treated with metformin–sulfonylurea combination: results of a multicenter, cross-sectional, observational study in korea
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420564/
https://www.ncbi.nlm.nih.gov/pubmed/25969717
http://dx.doi.org/10.1111/jdi.12284
work_keys_str_mv AT kimsingon assessmentofglycemiccontrolinpatientswithtype2diabetesmellitustreatedwithmetforminsulfonylureacombinationresultsofamulticentercrosssectionalobservationalstudyinkorea
AT hahmjongryeal assessmentofglycemiccontrolinpatientswithtype2diabetesmellitustreatedwithmetforminsulfonylureacombinationresultsofamulticentercrosssectionalobservationalstudyinkorea
AT kimdukkyu assessmentofglycemiccontrolinpatientswithtype2diabetesmellitustreatedwithmetforminsulfonylureacombinationresultsofamulticentercrosssectionalobservationalstudyinkorea
AT chosungrae assessmentofglycemiccontrolinpatientswithtype2diabetesmellitustreatedwithmetforminsulfonylureacombinationresultsofamulticentercrosssectionalobservationalstudyinkorea
AT choidongseop assessmentofglycemiccontrolinpatientswithtype2diabetesmellitustreatedwithmetforminsulfonylureacombinationresultsofamulticentercrosssectionalobservationalstudyinkorea